The
various lipid formulations of AMB have demonstrated antifungal efficacy at
least equivalent to the conventional
product with significantly reduced nephrotoxicity. In: THE USE OF LIPID
FORMULATIONS OF
AMPHOTERICIN B IN CANCER PATIENTS --
Rod Quilitz, PharmD, Department of Pharmacy, H. Lee Moffitt Cancer Center & Research
Institute, University of San Francisco, Cal.
http://www.moffitt.usf.edu/cancjrnl/v5n5/department3.html